-
Mashup Score: 0Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancer - 1 month(s) ago
AbstractBackground. Osimertinib is the first-line therapy for patients with non-small cell lung cancer harboring epidermal growth factor receptor–activatin
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
In ADAURA, adjuvant osimertinib significantly improved disease-free survival versus placebo in resected stage IB to IIIA EGFR-mutated NSCLC. We report in-depth analyses of three-year safety, tolerability, and health-related quality of life (HRQoL) from ADAURA.
Source: www.jto.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this report after an in-depth analyses of 3-year safety, tolerability, and HRQoL from ADAURA, no new safety signals were reported and HRQoL was maintained w 3 years of adjuvant #osimertinib treatment. https://t.co/cedZaeFWUS @margamajem @maryjofidlermd #LCSM https://t.co/UEONXMHPQp
-
-
Mashup Score: 2Lung Cancer Survivor Jill Feldman Offers Hope With Her Journey - 9 month(s) ago
In this special episode, The Oncology Brothers focus on the center of personalized medicine: the patient. Patient advocate and lung cancer survivor Jill Feldman details her lung cancer journey, from early-stage disease to advanced stage with metastases. Jill, who is a co-founder of the EGFR Resisters, an advocacy group that aims to improve outcomes for people with EG FR-positive lung cancer, speaks about how novel therapies have provided her with the opportunity to live out her life and spend quality
Source: docwirenews.comCategories: Latest Headlines, Partners & KOLsTweet-
Patient’s #LungCancer journey (@jillfeldman4), the importance of NGS testing (in early & metastatic settings), and patient perspective + advocacy in #Cancer is critical! https://t.co/BhgZcS8Bco #lcsm #osimertinib #MedTwitter #OncTwitter @HemOncFellows @mydocwire @ThanksCancer
-
-
Mashup Score: 3Combining Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes | SWOG - 10 month(s) ago
Clinical Trial Summary (S1900G) What is the purpose of this clinical trial? This study tests targeted treatments for people with advanced non-small cell lung cancer that has certain changes (mutations) in both the EGFR and MET genes. Finding these changes gives your doctor more information about what is causing the…
Source: www.swog.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#NSCLC that gets worse after treatment with #osimertinib (#Tagrisso) sometimes has new changes in the MET gene. @LungMAP sub-study S1900G is for people with both #EGFR and MET gene changes. Learn more at https://t.co/XTQjB48soc. Or call 1-800-4-CANCER. Ask about S1900G. #lcsm https://t.co/9HvnSlkqhp
-
-
Mashup Score: 0Adjuvant Osimertinib Improved Overall Survival for Patients With EGFR-Mutant NSCLC - 10 month(s) ago
At the 2023 ASCO Annual Meeting, Roy Herbst, MD, PhD, shared results from the overall survival analysis of the phase 3 ADAURA trial, evaluating adjuvant osimertinib for patients with resected EGFR-mutated non-small cell lung cancer.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Here, @DrRoyHerbstYale, discusses results from the overall survival analysis of the phase 3 #ADAURA trial, as presented at the 2023 @ASCO Annual Meeting. Learn more: https://t.co/xcKUgyQ655 #onctwitter #medtwitter #NSCLC #osimertinib https://t.co/iaWrYpEEdT
-
-
Mashup Score: 0Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC | NEJM - 10 month(s) ago
Original Article from The New England Journal of Medicine — Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Source: www.nejm.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Overall Survival with #Osimertinib in Resected EGFR-Mutated NSCLC 👉https://t.co/xyEN3FFcnN @NEJM https://t.co/DAFkq9dyxs
-
-
Mashup Score: 0Ways to Manage Toxicities Related to Osimertinib for Lung Cancer - 10 month(s) ago
Mark A. Socinski, MD, discusses his approach to managing toxicities related to osimertinib for patients with non–small cell lung cancer and EGFR mutations.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Mark A. Socinski, MD, discusses managing toxicities related to #osimertinib in EGFR-mutated #NSCLC. #lcsm | @AdventHealth https://t.co/V4VJRhpAFA
-
-
Mashup Score: 0Adjuvant Osimertinib for Resected EFGR-Mutated Stage Ib-IIIA NSCLC - 11 month(s) ago
Interview with David Henry MD
Source: PracticeUpdateCategories: Hem/Oncs, Latest HeadlinesTweet-
Adjuvant #Osimertinib for Resected #EFGR-Mutated Stage Ib-IIIA #NSCLC 👉https://t.co/MCA6HmcVuj @ASCO #LungCancer #ConferenceHighlights https://t.co/OKJKykM3eL
-
-
Mashup Score: 0Osimertinib: Game-Changing Treatment Non-Small Cell Lung Cancer - 11 month(s) ago
by: Tom John, MBBS, PhD, FRACP – Peter MacCallum Cancer Centre Tom John is a medical oncologist specializing in thoracic malignancies, with a particular focus on lung cancer and mesothelioma, and his groundbreaking clinical trials and translational research have significantly impacted the field, leading to advanceme…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🫁 #Osimertinib 🫁 #ASCO23 Game-Changing Treatment for Non-Small Cell Lung Cancer by @TommyJohn00 @PeterMacCC great video https://t.co/YD9omMYVjp #NSCLC https://t.co/LPxSh3nhlX
-
-
Mashup Score: 2Ways to Manage Toxicities Related to Osimertinib for Lung Cancer - 11 month(s) ago
Mark A. Socinski, MD, discusses his approach to managing toxicities related to osimertinib for patients with non–small cell lung cancer and EGFR mutations.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Mark A. Socinski, MD, discusses his approach to managing toxicities related to #osimertinib for patients with non–small cell lung cancer and EGFR mutations. #nsclc #lcsm | @AdventHealth https://t.co/LLL38mE7g1
-
Lu et al. reported treatment with G-quadruplex ligands that suppress c-FOS expression, in combination with #osimertinib, offers a potential strategy to inhibit osimertinib-resistant non-small cell lung cancer. Read more here: https://t.co/GYj7E0MGlu https://t.co/mgb8amreae